Morgan Stanley Neu Base Therapeutics, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.17 - $0.39 $6 - $14	-37 Reduced 19.79%	150 $0
Q4 2022 Feb 14, 2023	BUY	$0.18 - $0.3 $6 - $11	37 Added 24.67%	187 $0
Q3 2022 Nov 14, 2022	SELL	$0.41 - $1.3 $33 - $105	-81 Reduced 35.06%	150 $0
Q2 2022 Oct 27, 2022	SELL	$0.82 - $1.93 $654 - $1,540	-798 Reduced 77.55%	231 $0
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.93 $654 - $1,540	-798 Reduced 77.55%	231 $0
Q1 2022 Oct 27, 2022	BUY	$1.26 - $2.95 $1,005 - $2,354	798 Added 345.45%	1,029 $2,000
Q1 2022 May 13, 2022	SELL	$1.26 - $2.95 $10,568 - $24,744	-8,388 Reduced 89.07%	1,029 $2,000
Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $132,113 - $212,398	-50,813 Reduced 84.36%	9,417 $26,000
Q3 2021 Nov 15, 2021	BUY	$3.27 - $4.76 $196,952 - $286,694	60,230 New	60,230 $218,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.